Q-omics provides the consensus-scored RPL17P22 profile across patient tissues and cancer cell-line models. RPL17P22 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL17P22 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, RPL17P22 RNA expression shows 14,481 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight ACC, KIRC, and DLBC as cancer lineages where RPL17P22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL17P22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL17P22 survival associations across molecular data types. RPL17P22 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL17P22 RNA expression–survival associations across cancer types. High RPL17P22 expression shows unfavorable associations in ACC, LIHC, UCEC, SARC and PAAD, but favorable associations in CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL17P22 RNA expression.
This table summarizes RPL17P22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL17P22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL17P22 shows lower tumor expression in BRCA, HNSC and BLCA and higher tumor expression in KIRC and CHOL. The KIRC box plot shows higher RPL17P22 RNA expression in tumor versus normal tissue (log2 FC = +0.244, t-test p < 0.001).
This table shows molecular features associated with RPL17P22 in patient tissues and cancer cell lines. In patient samples, RPL17P22 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
